Therapy Areas: Allergy
DBV Technologies secures up to USD306.9m to advance Viaskin peanut patch programme
28 March 2025 - Clinical-stage biopharmaceutical company DBV Technologies (Euronext Paris:DBV) (Nasdaq Capital Market:DBVT) on Friday announced a financing agreement of up to USD306.9m (EUR284.5m), in...
Celltrion's OMLYCLO receives US FDA approval
10 March 2025 - South Korea-based biopharmaceutical company Celltrion announced on Sunday that it has received approval from the US Food and Drug Administration (FDA) for the company's OMLYCLO (o...
Kenox Pharmaceuticals partners with Lactiga US
10 March 2025 - United States-based company that specialises in pharmaceutical aerosol product development Kenox Pharmaceuticals Inc. announced on Monday that is partnering with Lactiga US, Inc, a bio...
Health Canada approves ALK's ACARIZAX for young children with dust mite allergy
7 March 2025 - Danish pharmaceutical company ALK-Abelló A/S (ALK) (CPH:ALK-B) said on Friday that it has received approval from Health Canada for its ACARIZAX tablet to treat children aged five...
Allergy Therapeutics publishes positive Phase III data for Grass MATA MPL
17 February 2025 - Biotechnology company Allergy Therapeutics (AIM: AGY) announced on Monday that it has published Phase III trial data for its subcutaneous immunotherapy Grass MATA MPL in the journal...
CSL's ANDEMBRY receives European approval to prevent attacks of hereditary angioedema
14 February 2025 - Australian biotechnology company CSL (ASX:CSL; USOTC:CSLLY) announced on Thursday that it has received approval from the European Commission for ANDEMBRY (garadacimab), the first an...